A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin Rash
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Epidermal growth factor receptor inhibitors (EGFRIs) are widely used targeted agents that
have been approved for the treatment of various tumor types. In some clinical studies with
EGFRIs, the incidence of dermatology AE, the skin rash, is reportedly as high as 95%, which
profoundly impact the patients' quality of life. However no treament for onset skin rash has
been approved to be effective by any clinical trial yet. Janus kinase (JAK) inhibitor, has
been approved for or studied in a variety of skin conditions such as alopecia areata, atopic
dermatitis, and psoriasis. Thus we intend to evaluate the efficacy and safety of JAK
inhibitor cream for the treatment of EGFRIs-induced skin rash in cancer patients.